ClinicalTrials.gg
CompletedNCT03902509Updated May 4, 2025

A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

A Phase 2 interventional study of Pirfenidone and basic treatment in Radiation-induced Lung Injury, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Lung Injury with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Lung Injury · China.

Enrollment
5th of 18
126 · median 100
Started
2019
with 1 other
Phase 2
Only one
of the 22
Registered
6th of 22
by date
Lead sponsor
2 of 22
Beijing Continent Pharmaceutical Co, Ltd.

Among the 22 studies in Lung Injury with a site in China, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2019, is the only one in phase 2, and was the 6th registered.

Lung Injury

114 studies on the registry are indexed under Lung Injury; 33 are open to participants now.

Browse Lung Injury studies →

Open to participants now

10 of the 22 studies in Lung Injury with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Lung Injury studies recruiting now, 12 (48%) set no upper age limit and 8 (32%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Lung Injury with a site in China, or all of them as a file.
02

Study summary

Using Pirfenidone to treat Grade 2 or Grade3 radiation-induced lung injury, and observe the efficacy and safety of the drug.

Read the detailed description

The study is a randomized, controlled, multi-site clinical trial.

03

Conditions studied

  • Radiation-induced Lung Injury

Browse trials for

Keywords

  • pirfenidone
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-75 years old (including 18 and 75 years);
  2. clinically diagnosed grade 2 or 3 radiation-induced lung injury;
  3. the course of radiation-induced lung injury is less than 2 months;
  4. 0-2;
  5. the expected survival time is more than 6 months;
  6. the functional level of major organs meets the following standards: ≥3.0×109/L,≥100×109/L,≥90g/L, 、BUN and Cr≤1.5×, 、AST≤2.0×ULN
  7. capable of eating solid food upon enrollment;
  8. subjects will voluntarily participate in this study and sign the .

Exclusion criteria

Exclusion Criteria:

  1. have a history of chronic bronchial acute attack or severe pulmonary heart disease;
  2. pneumonectomy;
  3. tumor progression;
  4. severe pulmonary infection;
  5. rate \< 30ml/min, severe renal disease or need dialysis;
  6. concomitant with other serious diseases: for example, myocardial infarction within 6 months, uncontrolled diabetes, etc., were considered not suitable for the participants in the study;
  7. patients with active peptic ulcer;
  8. pregnant women and patients with mental illness;
  9. participating in clinical trials of other drugs within 3 months;
  10. the investigator determined that subject was not suitable.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Pirfenidone

    pirfenidone + basic treatment

    Drug: Pirfenidone · Drug: basic treatment

  • Other
    Controll

    with basic treatment and without pirfenidone treatment

    Drug: basic treatment

Interventions

  • pirfenidone capsule made in China

  • Drugbasic treatment

    glucocorticoid and expectant treatment etc.

06

What researchers measure

Primary outcomes

  1. DLco% change

    Compare DLco% from basement to the end of treatment

    Time frame: Week 4, 8,16, and 24

Secondary outcomes

  1. The grade change of radiation-induced lung injury

    Time frame: Week 4, 8,16, and 24

  2. The score change of CT

    Time frame: Week 4, 8,16, and 24

  3. Increase of effective lung volume

    Time frame: Week 4, 8,16, and 24

  4. The grade change of Cough, Dyspnea and Fever

    Time frame: Week 4, 8,16, and 24

07

Study locations

2 sites
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing 100021, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Dec 2023, 54 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2019
First posted
Apr 4, 2019
StartActual
May 24, 2019
Primary completionActual
Dec 4, 2023
CompletionActual
Dec 4, 2023
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03902509
Responsible party
Sponsor
First posted
Apr 4, 2019
Start date
May 24, 2019
Primary completion
Dec 4, 2023
Completion
Dec 4, 2023
Last update
May 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion